Jared Weiss1, Jill Gilbert2, Allison Mary Deal3, Mark Weissler4, Chris Hilliard5, Bhishamjit Chera6, Barbara Murphy7, Trevor Hackman8, Jay Justin Liao9, Juneko Grilley Olson10, David Neil Hayes11. 1. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: Jared_Weiss@med.unc.edu. 2. Vanderbilt-Ingram Cancer Center, United States. Electronic address: jill.gilbert@vanderbilt.edu. 3. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: allison_deal@med.unc.edu. 4. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: mark_weissler@med.unc.edu. 5. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: chris_hilliard@med.unc.edu. 6. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: bchera@med.unc.edu. 7. Vanderbilt-Ingram Cancer Center, United States. Electronic address: barbara.murphy@vanderbilt.edu. 8. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: trevor_hackman@med.unc.edu. 9. University of Washington/Seattle Cancer Care Alliance, United States. Electronic address: ayliao@uw.edu. 10. University of North Carolina Lineberger Comprehensive Cancer Center, United States. Electronic address: juneko_grilley-olson@med.unc.edu. 11. West Cancer Center at the University of Tennessee, United States. Electronic address: neil.hayes@uthsc.edu.
Abstract
BACKGROUND: Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity. MATERIALS AND METHODS: Patients with treatment naïve SCCHN of any site with ≥N2b disease or that was unresectable by strict criteria were eligible. Patients were treated with nab-paclitaxel 100 mg/m2, CbP area under the curve (AUC) 2 and C225 400 mg/m2 week 1 then 250 mg/m2 for six weeks, followed by standard of care chemoradiotherapy (CRT). The primary endpoint was clinical response rate to induction therapy as defined by RECIST version 1.1. Secondary measures included toxicity, progression-free survival, overall survival and quality of life as measured by FACT-HN. RESULTS: 38 eligible subjects were treated. Primary sites were: oropharynx (OPX) (25), larynx (3) oral cavity (OC) (9), hypopharynx (1). The most common grade 3 or 4 toxicity during induction was acneiform rash (26%) followed by neutropenia (16%). RR was 76.3%. Median PFS and OS have not been reached (median follow-up of 3.3 years); they were superior in patients with response. CONCLUSIONS: The combination of nab-paclitaxel, CbP and C225 is feasible, tolerable and active against locally advanced SCCHN.
BACKGROUND: Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity. MATERIALS AND METHODS:Patients with treatment naïve SCCHN of any site with ≥N2b disease or that was unresectable by strict criteria were eligible. Patients were treated with nab-paclitaxel 100 mg/m2, CbP area under the curve (AUC) 2 and C225 400 mg/m2 week 1 then 250 mg/m2 for six weeks, followed by standard of care chemoradiotherapy (CRT). The primary endpoint was clinical response rate to induction therapy as defined by RECIST version 1.1. Secondary measures included toxicity, progression-free survival, overall survival and quality of life as measured by FACT-HN. RESULTS: 38 eligible subjects were treated. Primary sites were: oropharynx (OPX) (25), larynx (3) oral cavity (OC) (9), hypopharynx (1). The most common grade 3 or 4 toxicity during induction was acneiform rash (26%) followed by neutropenia (16%). RR was 76.3%. Median PFS and OS have not been reached (median follow-up of 3.3 years); they were superior in patients with response. CONCLUSIONS: The combination of nab-paclitaxel, CbP and C225 is feasible, tolerable and active against locally advanced SCCHN.
Authors: Kai C C Johnson; Jessica Ley; Peter Oppelt; Jingxia Lu; Hiram A Gay; Mackenzie Daly; Ryan Jackson; Jason Rich; Patrik Pipkorn; Randal C Paniello; Jose Zevallos; Wade Thorstad; Douglas R Adkins Journal: Med Oncol Date: 2019-10-08 Impact factor: 3.064
Authors: Ari J Rosenberg; Nishant Agrawal; Alexander T Pearson; Zhen Gooi; Elizabeth Blair; Louis Portugal; John F Cursio; Aditya Juloori; Jeffrey Chin; Kathryn Rouse; Victoria M Villaflor; Tanguy Y Seiwert; Evgeny Izumchenko; Mark W Lingen; Daniel J Haraf; Everett E Vokes Journal: Br J Cancer Date: 2022-08-09 Impact factor: 9.075
Authors: José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez Journal: Front Oncol Date: 2022-08-01 Impact factor: 5.738